Response to Eribulin in a Difficult-To-Treat Triple Negative Breast Cancer Patient-Juniper Publishers
Response to Eribulin in a Difficult-To-Treat Triple NegativeBreast Cancer Patient by Raul Marquez Vazquez in Juniper Publishers in InternationalJournal of Cell Science & Molecular Biology In this paper, we report our experience with eribulinmesylate in a locally advanced triple negative breast cancer (BC) patient who was treated with antracyclines and taxanes, and became metastatic. After one refractory line with Capecitabine and Bevacizumab, there was response to Eribulin. No unexpected acute toxicity was observed. https://juniperpublishers.com/ijcsmb/IJCSMB.MS.ID.555559.php For more Open access journals please click on JuniperPublishers : https://juniperpublishers.com/ For more articles please click on International Journal ofCell Science & Molecular Biology : https://juniperpublishers.com/ijcsmb/index.php